首页> 美国卫生研究院文献>Antimicrobial Agents and Chemotherapy >Genome Expression Profiling-Based Identification and Administration Efficacy of Host-Directed Antimicrobial Drugs against Respiratory Infection by Nontypeable Haemophilus influenzae
【2h】

Genome Expression Profiling-Based Identification and Administration Efficacy of Host-Directed Antimicrobial Drugs against Respiratory Infection by Nontypeable Haemophilus influenzae

机译:基于基因组表达谱的宿主导向型抗菌药物对不可分型流感嗜血杆菌的呼吸道感染的鉴定和给药效果

代理获取
本网站仅为用户提供外文OA文献查询和代理获取服务,本网站没有原文。下单后我们将采用程序或人工为您竭诚获取高质量的原文,但由于OA文献来源多样且变更频繁,仍可能出现获取不到、文献不完整或与标题不符等情况,如果获取不到我们将提供退款服务。请知悉。

摘要

Therapies that are safe, effective, and not vulnerable to developing resistance are highly desirable to counteract bacterial infections. Host-directed therapeutics is an antimicrobial approach alternative to conventional antibiotics based on perturbing host pathways subverted by pathogens during their life cycle by using host-directed drugs. In this study, we identified and evaluated the efficacy of a panel of host-directed drugs against respiratory infection by nontypeable Haemophilus influenzae (NTHi). NTHi is an opportunistic pathogen that is an important cause of exacerbation of chronic obstructive pulmonary disease (COPD). We screened for host genes differentially expressed upon infection by the clinical isolate NTHi375 by analyzing cell whole-genome expression profiling and identified a repertoire of host target candidates that were pharmacologically modulated. Based on the proposed relationship between NTHi intracellular location and persistence, we hypothesized that drugs perturbing host pathways used by NTHi to enter epithelial cells could have antimicrobial potential against NTHi infection. Interfering drugs were tested for their effects on bacterial and cellular viability, on NTHi-epithelial cell interplay, and on mouse pulmonary infection. Glucocorticoids and statins lacked in vitro and/or in vivo efficacy. Conversely, the sirtuin-1 activator resveratrol showed a bactericidal effect against NTHi, and the PDE4 inhibitor rolipram showed therapeutic efficacy by lowering NTHi375 counts intracellularly and in the lungs of infected mice. PDE4 inhibition is currently prescribed in COPD, and resveratrol is an attractive geroprotector for COPD treatment. Together, these results expand our knowledge of NTHi-triggered host subversion and frame the antimicrobial potential of rolipram and resveratrol against NTHi respiratory infection.
机译:对于抵抗细菌感染,非常需要安全,有效且不易产生耐药性的疗法。基于宿主的疗法是一种抗微生物方法,可替代常规抗生素,其基础是使用宿主导向的药物干扰病原体在其生命周期中颠覆的宿主途径。在这项研究中,我们确定并评估了一组针对宿主的药物对抗非典型流感嗜血杆菌(NTHi)呼吸道感染的功效。 NTHi是一种机会病原体,是慢性阻塞性肺疾病(COPD)恶化的重要原因。我们通过分析细胞全基因组表达谱,筛选了临床分离株NTHi375感染后差异表达的宿主基因,并鉴定了经过药理调节的宿主靶标候选库。基于建议的NTHi细胞内位置和持久性之间的关系,我们假设扰动NTHi进入宿主上皮细胞的宿主途径的药物可能具有抗NTHi感染的抗菌潜力。测试了干扰药物对细菌和细胞生存力,NTHi-上皮细胞相互作用以及对小鼠肺部感染的影响。糖皮质激素和他汀类药物缺乏体外和/或体内功效。相反,sirtuin-1激活剂白藜芦醇显示出对NTHi的杀菌作用,而PDE4抑制剂rolipram通过降低感染小鼠的细胞内和肺中的NTHi375计数显示出治疗效果。目前在COPD中规定了对PDE4的抑制作用,白藜芦醇是用于COPD治疗的有吸引力的代孕保护剂。总之,这些结果扩展了我们对NTHi触发的宿主颠覆的认识,并构建了咯利普兰和白藜芦醇对NTHi呼吸道感染的抗菌潜力。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
代理获取

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号